nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

29.04.2022 | Cornea

Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients

verfasst von: Daeun Shin, Ji Sang Min

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to investigate the difference in the treatment effects of 4.9% N-acetyl-aspartyl glutamic acid (NAAGA) and 0.05% cyclosporine A (CsA) eye drops in dry eye patients.

Methods

We retrospectively reviewed the medical records of 86 patients (86 eyes) who were diagnosed with dry eye and treated with NAAGA or CsA eye drops. Patients treated with NAAGA or CsA eye drops were designated as group A or B, respectively. We also calculated Ocular Surface Disease Index (OSDI), dry eye, and meibomian gland dysfunction (MGD) parameters before treatment and at 1 and 3 months after treatment. Eye drop discomfort was assessed by calculating visual analog scale (VAS) scores at 1 month and 3 months after treatment.

Results

There were no significant differences in patients’ demographics and OSDI, dry eye, and MGD parameters between the two groups. OSDI, dry eye, and MGD parameters at 1 month and 3 months after treatment were found to be improved in both groups. However, at 1 month after treatment, the dry eye and MGD parameters of group A, except for corneal fluorescein staining, showed more improvement than those of group B. Additionally, at 3 months after treatment, the lid margin abnormality score, corneal staining score, tear break-up time, and OSDI of group A were significantly lower than those of group B. VAS scores of group A at 1 and 3 months after treatment were significantly lower than those of group B.

Conclusion

Treatment with NAAGA eye drops was effective in dry eye patients and demonstrated faster treatment response and less discomfort during application than CsA eye drops.

Lemp MA, Foulks GN (2007) The definition and classification of dry eye disease. Ocul Surf 5:75–92CrossRef

Yamaguchi T (2018) Inflammatory response in dry eye. Invest Ophthalmol Vis Sci 59:DES192–DES199CrossRef

Chen D, Zhang S, Bian A, Hong J, Deng Y, Zhang M, Chen W, Shao Y, Zhao J (2019) Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. Medicine 98:e16710

Wan KH, Chen LJ, Young AL (2015) Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf 13:213–225CrossRef

Bonnet M, Ducournau D, Lumbroso P, Serpin G (1985) N-acetyl-aspartylglutamic acid eye drops in allergic-type conjuctivitis. Double-blind comparative clinical study. J Fr Ophtalmol 8:573–578PubMed

Berard P, Berard P Jr, Mouillac-Gambarelli N, Jourdan-Fonta D (1987) Seasonal and chronic allergic conjunctivitis in adults with children. Multicenter evaluation of the collyrium N-acetylaspartylglutamic acid (NAAGA) in ophthalmologic and allergy practices. Bull Soc Ophtalmol Fr 87:475–483PubMed

Leonardi A, Bremond-Gignac D, Bortolotti M, Violato D, Pouliquen P, Delval L, Grouin J-M, Fregona I (2007) Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 91:1662–1666CrossRef

Gündüz K, Uçakhan Ö, Budak K, Eryilmaz T, Özkan M (1996) Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis. Ophthalmic Res 28:80–87CrossRef

Etievant M, Leluc B, David B (1988) In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA). Agents Actions 24:137–144CrossRef

10.

Brignole-Baudouin F, Robert P, Creuzot-Garcher C, Olmiere C, Delval L, Baudouin C (2009) Evaluation of NAAGA efficacy in dry eye syndrome. J Fr Ophtalmol 32:613–620CrossRef

11.

Matossian C, Trattler W, Loh J (2021) Dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate ophthalmic emulsion. Clin Ophthalmol 15:1979CrossRef

12.

Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640–650CrossRef

13.

Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN (2011) The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 52:1930–1937CrossRef

14.

Rhee MK, Mah FS (2017) Inflammation in dry eye disease: how do we break the cycle? Ophthalmology 124:S14–S19CrossRef

15.

Baudouin C, Brignole F, Becquet F, Pisella P-J, Goguel A (1997) Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation. Invest Ophthalmol Vis Sci 38:1458–1464PubMed

16.

Tsubota K, Fujihara T, Saito K, Takeuchi T (1999) Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica 213:16–19CrossRef

17.

Brignole-Baudouin F, Riancho L, Ismail D, Deniaud M, Amrane M, Baudouin C (2017) Correlation between the inflammatory marker HLA-DR and signs and symptoms in moderate to severe dry eye disease. Invest Ophthalmol Vis Sci 58:2438–2448CrossRef

18.

Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue J-S, Figueiredo FC, Baudouin C (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26:287–296CrossRef

19.

Periman LM, Perez VL, Saban DR, Lin MC, Neri P (2020) The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther 36:137–146CrossRef

20.

Gao J, Sana R, Calder V, Calonge M, Lee W, Wheeler LA, Stern ME (2013) Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci 54:4717–4733CrossRef

21.

Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, SkoPińSki P (2016) Immunomodulation on the ocular surface: a review. Cent Eur J Immunol 41:195CrossRef

22.

Meyer S, Kohler NG, Joly A (1997) Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation. FEBS Lett 413:354–358CrossRef

23.

Dastjerdi MH, Hamrah P, Dana R (2009) High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28:1091CrossRef

24.

Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y (2017) TFOS DEWS II management and therapy report. Ocul Surf 15:575–628CrossRef

25.

Sy A, O’Brien KS, Liu MP, Cuddapah PA, Acharya NR, Lietman TM, Rose-Nussbaumer J (2015) Expert opinion in the management of aqueous deficient dry eye disease (DED). BMC Ophthalmol 15:1–6CrossRef

26.

Wan P, Wang X, Song Y, Li Z, Duan H, Zhang W, Liu Z, Wang Z (2012) Study on the treatment of dry eye with loteprednol etabonate. Zhonghua Yan Ke Za Zhi 48:142–147

27.

Sheppard JD, Scoper SV, Samudre S (2011) Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther 27:23–27CrossRef

28.

Pavesio CE, DeCory HH (2008) Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 92:455–459CrossRef

Titel: Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients
verfasst von: Daeun Shin
Ji Sang Min
Publikationsdatum: 29.04.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2022
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-022-05682-x

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Progression and associated factors of lacquer cracks/patchy atrophies in high myopia: the Beijing Eye Study 2001–2011

Clinical Characteristics of recurrent intraocular lens dislocation after scleral-fixated sutured intraocular lens and long-term outcomes of intraocular lens re-fixation

Rotational extraction of incarcerated iris (REII): a slit lamp technique to reduce incarcerated iris after nonpenetrating deep sclerectomy for glaucoma

nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey

Rhegmatogenous retinal detachment repair—does age, sex, and lens status make a difference?

Impact of cone base diameter on outcomes of deep anterior lamellar keratoplasty in keratoconus

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde